Artelo Biosciences (NASDAQ:ARTL) versus RenovoRx (NASDAQ:RNXT) Critical Analysis

RenovoRx (NASDAQ:RNXT) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Insider and Institutional Ownership

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 9.1% of RenovoRx shares are owned by insiders. Comparatively, 11.5% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares RenovoRx and Artelo Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RenovoRx	-1,196.66%	-122.19%	-90.69%
Artelo Biosciences	N/A	-3,401.09%	-345.03%

Analyst Recommendations

This is a breakdown of current ratings and target prices for RenovoRx and Artelo Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1	0	2	1	2.75
Artelo Biosciences	1	2	0	0	1.67

RenovoRx currently has a consensus target price of $8.00, indicating a potential upside of 640.74%. Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 832.64%. Given Artelo Biosciences’ higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than RenovoRx.

Volatility & Risk

RenovoRx has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Valuation and Earnings

This table compares RenovoRx and Artelo Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$40,000.00	989.55	-$8.81 million	($0.36)	-3.00
Artelo Biosciences	N/A	N/A	-$12.88 million	($62.76)	-0.09

RenovoRx has higher revenue and earnings than Artelo Biosciences. RenovoRx is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

RenovoRx beats Artelo Biosciences on 10 of the 14 factors compared between the two stocks.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

About Artelo Biosciences

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.